A 52-year-old male with HER2-positive metastatic breast cancer is started on trastuzumab. Which is the most common serious adverse effect requiring cardiac monitoring during therapy?

Explanation

## Trastuzumab Cardiotoxicity **Key Point:** Trastuzumab-induced cardiomyopathy with LVEF decline and congestive heart failure is the most common and clinically significant cardiac adverse effect, occurring in 5–7% of patients and up to 27% when combined with anthracyclines. ### Mechanism of HER2 Antibody Cardiotoxicity ```mermaid flowchart TD A[Trastuzumab binds HER2 on cardiomyocytes]:::action --> B[Inhibits HER2-mediated survival signaling]:::action B --> C[Loss of PI3K/Akt and MAPK pathway activation]:::action C --> D[Increased oxidative stress & mitochondrial dysfunction]:::action D --> E[Cardiomyocyte apoptosis & dysfunction]:::action E --> F[LVEF decline & dilated cardiomyopathy]:::outcome F --> G[Congestive heart failure]:::urgent ``` ### Risk Factors for Trastuzumab Cardiotoxicity - **Prior or concurrent anthracycline chemotherapy** (cumulative dose >300 mg/m²) - Age >50 years - Baseline LVEF <55% - Hypertension or diabetes - Prior cardiac disease ### Monitoring Protocol | Timepoint | Investigation | Action | |-----------|---------------|--------| | **Baseline** | ECHO/MUGA (LVEF) | Must be ≥55% to start | | **Every 3 months** | ECHO/MUGA | Continue if LVEF ≥50% | | **LVEF decline >10% or <50%** | Hold trastuzumab | Cardiology consult; consider ACE-I/beta-blocker | | **Symptomatic HF** | Urgent ECHO | Discontinue; initiate HF therapy | **High-Yield:** Trastuzumab cardiotoxicity is **reversible** in ~50% of cases with HF therapy (ACE inhibitors, beta-blockers), unlike anthracycline cardiomyopathy. ### Clinical Pearl **Trastuzumab-induced LVEF decline is NOT the same as acute myocarditis.** It is a chronic, dose-dependent cardiomyopathy that develops insidiously over weeks to months. Patients typically remain asymptomatic until LVEF drops significantly. ### Management Strategy 1. **Baseline ECHO:** Ensure LVEF ≥55% before starting 2. **Serial monitoring:** ECHO every 3 months during therapy 3. **Dose modification:** Hold if LVEF declines >10% from baseline or falls <50% 4. **Cardioprotection:** Consider prophylactic ACE-I or beta-blocker in high-risk patients 5. **Continuation:** Can often resume after LVEF recovery with cardiac support **Warning:** Do NOT confuse trastuzumab cardiotoxicity with acute myocarditis or ACS—these are rare with trastuzumab and would present with acute chest pain, troponin elevation, and ST changes. Trastuzumab-induced LVEF decline is asymptomatic until advanced. [cite:Harrison 21e Ch 100; ASCO Guidelines 2023]